Proficio Capital Partners LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,174 shares of the biopharmaceutical company's stock, valued at approximately $306,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the business. Cookson Peirce & Co. Inc. increased its position in shares of TG Therapeutics by 61.7% during the 4th quarter. Cookson Peirce & Co. Inc. now owns 28,081 shares of the biopharmaceutical company's stock valued at $845,000 after purchasing an additional 10,718 shares during the last quarter. Victory Capital Management Inc. increased its holdings in TG Therapeutics by 65.3% during the fourth quarter. Victory Capital Management Inc. now owns 54,034 shares of the biopharmaceutical company's stock worth $1,626,000 after buying an additional 21,355 shares during the last quarter. Westover Capital Advisors LLC bought a new stake in TG Therapeutics in the fourth quarter worth about $214,000. Charles Schwab Investment Management Inc. raised its position in TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock worth $38,212,000 after acquiring an additional 84,904 shares during the period. Finally, Jones Financial Companies Lllp boosted its stake in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 1,737 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $40.67.
Read Our Latest Stock Report on TGTX
TG Therapeutics Stock Performance
Shares of TGTX stock traded down $0.34 during trading on Friday, reaching $39.86. 1,642,962 shares of the company's stock traded hands, compared to its average volume of 3,069,404. The firm's 50-day moving average is $34.37 and its 200 day moving average is $30.39. The company has a market capitalization of $6.26 billion, a P/E ratio of -398.56 and a beta of 2.30. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.
Insider Buying and Selling
In related news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.50% of the stock is currently owned by insiders.
About TG Therapeutics
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Stories
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
